Opadry® amb II High Performance Moisture Barrier Film Coating
Opadry amb II, high performance moisture barrier film coating, is the first fully formulated PVA-based immediate release system without polyethylene glycol (PEG) that delivers the three-fold advantage of high productivity, low impurity levels and a superior tablet finish. Tablets coated with Opadry amb II exhibit a high-gloss, quality appearance with well-defined logos.
The Perfect Balance – Protection, Time Savings, Ease-of-Use
Product LiteratureGeneral Information Product Process Parameters Product Recon Sheet Product Brochure Published Posters Published White Papers / Articles
Product Process Parameters
Product Recon Sheet
AAPS 2014 - A Novel Method to Evaluate On-tablet Moisture Barrier Performance of Opadry® Film Coating SystemsView and Download Send by Email
Use of dynamic vapor sorption (DVS) methodology to study the on tablet moisture barrier performance of four IR moisture barrier film coating systems including results on the influence of various coating weight gains.
AAPS 2014 - Evaluation of a Novel, PEG-free, Immediate Release Opadry® Aqueous Moisture Barrier Film Coating with High ProductivityView and Download Send by Email
Characterization of the properties of ibuprofen tablets coated with a novel, polyethylene glycol (PEG)-free, fully formulated immediate release, moisture barrier film coating system.
AAPS 2016 Utilization of a Moisture Barrier Film Coating to Enhance In-Use Tablet StabilityView and Download Send by Email
Study demonstrating the detrimental effects of even short-term exposure to the environment on the assay of clavulanic acid, after removal of tablets from their original package.
Published White Papers / Articles
Approved for Pharmaceutical Use
- Suitable for use in major pharmaceutical markets and developed using compendial ingredients that meet the regulatory requirements of the user, regionally or globally.
Colorcon can help to reduce your project time by providing the right solution through excipient selection and process guidance.
Lower total cost and reduce time to market
Life cycle management through modified delivery profiles and product line extensions
Reduce medication errors and improve patient adherence
Stable and consistent product performance
Track and trace